BR112014006105A2 - dosagem controlada de clopidogrel com terapias para a inibição de ácido gástrico - Google Patents

dosagem controlada de clopidogrel com terapias para a inibição de ácido gástrico

Info

Publication number
BR112014006105A2
BR112014006105A2 BR112014006105A BR112014006105A BR112014006105A2 BR 112014006105 A2 BR112014006105 A2 BR 112014006105A2 BR 112014006105 A BR112014006105 A BR 112014006105A BR 112014006105 A BR112014006105 A BR 112014006105A BR 112014006105 A2 BR112014006105 A2 BR 112014006105A2
Authority
BR
Brazil
Prior art keywords
clopidogrel
therapies
ppi
optionally
release
Prior art date
Application number
BR112014006105A
Other languages
English (en)
Inventor
R Plachetka John
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen Inc filed Critical Pozen Inc
Publication of BR112014006105A2 publication Critical patent/BR112014006105A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

controlled dosing of clopidogrel with gastric acid inhibition therapies abstract the present invention provides for novel formulations of clopidogrel in combination proton pump inhibitors (ppi), optionally with nsaids, for use as improved antiplatelet therapies in stroke and cardiovascular indications. ------------------------------------------------------------------------- tradução do resumo resumo patente de invenção: "dosagem controlada de clopidogrel com terapias para a inibição de ácido gástrico". a presente invenção fornece novas formulações de clopidogrel em combinação com inibidores da bomba de próton (ppi) e opcionalmente com nsaids, para uso como terapias anti-agregantes plaquetárias aperfei-çoadas em indicações como acidente vascular cerebral e cardiovasculares. a invenção fornece a liberação de clopidogrel em pulsos ou ondas, tal que a dose total é escalonada/distribuída ao longo do tempo e, vantajosamente, combinada com omeprazol de modo a minimizar as ações conflitantes que esses dois fármacos possam ter um co o outro. adicionalmente, a invenção também fornece a liberação de clopidogrel e um ppi e, opcionalmente, aspi-rina, em uma maneira sequencial (ordenadamente) que possa permitir a libe-ração e o metabolismo do clopidogrel primeiro, seguido pelo ppi e, depois, opcionalmente a aspirina. um modo particular da invenção envolve a combi-nação de clopidogrel coma liberação imediata de omeprazol coformulado + aspirina com revestimento entérico.
BR112014006105A 2011-09-14 2012-09-14 dosagem controlada de clopidogrel com terapias para a inibição de ácido gástrico BR112014006105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534666P 2011-09-14 2011-09-14
PCT/US2012/055574 WO2013040457A1 (en) 2011-09-14 2012-09-14 Controlled dosing of clopidogrel with gastric acid inhibition therapies

Publications (1)

Publication Number Publication Date
BR112014006105A2 true BR112014006105A2 (pt) 2017-04-11

Family

ID=47883798

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006105A BR112014006105A2 (pt) 2011-09-14 2012-09-14 dosagem controlada de clopidogrel com terapias para a inibição de ácido gástrico

Country Status (9)

Country Link
US (2) US20150079169A1 (pt)
EP (1) EP2755641A4 (pt)
CN (1) CN103906506A (pt)
BR (1) BR112014006105A2 (pt)
CA (1) CA2848764A1 (pt)
EA (1) EA029341B1 (pt)
MX (1) MX345717B (pt)
UA (1) UA115315C2 (pt)
WO (1) WO2013040457A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5905165B2 (ja) * 2013-08-02 2016-04-20 サノフイ アセチルサリチル酸およびクロピドグレルを含む医薬錠剤
CN106860398A (zh) * 2015-12-13 2017-06-20 北京蓝丹医药科技有限公司 一种高生物利用度的氯吡格雷药物组合物
CN107693524A (zh) * 2017-10-23 2018-02-16 罗铭炽 一种含阿司匹林和氯吡格雷的制备方法
CN107669690A (zh) * 2017-10-23 2018-02-09 罗铭炽 一种含阿司匹林和氯吡格雷的片剂
KR20200024413A (ko) 2018-08-28 2020-03-09 에이치케이이노엔 주식회사 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
UY39094A (es) 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN113350338A (zh) * 2021-07-09 2021-09-07 中荣凯特（北京）生物科技有限公司 用于抗血小板凝集同时合并其它疾病治疗的药物组合物及其应用
CN114159573B (zh) * 2022-01-27 2023-01-24 中以海德人工智能药物研发股份有限公司 一种用于治疗病毒性肝炎的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
KR20150105419A (ko) * 2006-04-04 2015-09-16 케이지 액퀴지션 엘엘씨 항혈소판제와 산 억제제를 포함하는 경구 투여 형태
WO2007113857A2 (en) * 2006-04-05 2007-10-11 Cadila Healthcare Limited Modified release clopidogrel formulation
NZ587179A (en) * 2008-01-25 2012-07-27 Theranostics Lab Detection of polymorphisms CYP2C19*17 and CYP2C19*3 in CYP2C19 gene related to antiplatelet drug metabolism (e.g. for clopidogrel metabolism)

Also Published As

Publication number Publication date
MX345717B (es) 2017-02-13
EP2755641A1 (en) 2014-07-23
EA201490625A1 (ru) 2014-08-29
UA115315C2 (uk) 2017-10-25
US20190030008A1 (en) 2019-01-31
EP2755641A4 (en) 2015-03-18
US20150079169A1 (en) 2015-03-19
EA029341B1 (ru) 2018-03-30
MX2014003216A (es) 2014-11-21
CA2848764A1 (en) 2013-03-21
CN103906506A (zh) 2014-07-02
WO2013040457A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
BR112014006105A2 (pt) dosagem controlada de clopidogrel com terapias para a inibição de ácido gástrico
PE20180931A1 (es) Metodo de cristalizacion y biodisponibilidad
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
BR112015005894A2 (pt) composição farmacêutica
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
MY181159A (en) Sublingual and buccal film compositions
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
JP2015038135A5 (pt)
BR112015030385A2 (pt) inibidores de pi3 delta e gama quinase seletivos duplos
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
PE20151374A1 (es) Regimen de dosificacion de un sedante
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
HRP20170651T1 (hr) Hpn-100 za uporabu za liječenje poremećaja retencije dušika
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
Pan et al. Synergistic interaction between choline and aspirin against acute inflammation induced by carrageenan and lipopolysaccharide
NZ599271A (en) Pharmaceutical compositions of rhein or diacerein
PH12015502706A1 (en) Oral formulation for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements